Seagen in licensing deal with Lava Therapeutics for cancer candidate

Sep. 26, 2022 8:18 AM ETSeagen Inc. (SGEN)MRK, LVTXBy: Dulan Lokuwithana, SA News Editor1 Comment

Solution Concept with Handshake on Chalkboard Background


  • Seagen Inc. (NASDAQ:SGEN) announced a license agreement with Dutch biotech LAVA Therapeutics N.V. (LVTX) on Monday for preclinical candidate LAVA-1223 which is designed to target epidermal growth factor receptor (EGFR)-expressing solid tumors.
  • Per the terms, SGEN will pay $50M upfront to LAVA to receive an exclusive worldwide license for LAVA-1223 which uses the latter's proprietary Gammabody technology.
  • The deal also includes up to about $650M milestone payments and royalties on future sales in the range of single digits to the mid-teens.
  • Additionally, the agreement gives SGEN, which focuses on antibody-drug conjugates for cancer, exclusive rights of negotiation to apply LAVA's Gammabody platform on up to two additional tumor targets.
  • LVTX shares have added ~113% pre-market in reaction to the deal, and SGEN is trading flat.
  • SGEN, which was rumored to have attracted buyout interest from Merck (MRK), lost in value in recent days as M&A prospects cooled.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.